# Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®

> **NCT01822028** · PHASE1 · COMPLETED · sponsor: **Actelion** · enrollment: 42 (actual)

## Conditions studied

- Diarrhea

## Interventions

- **DRUG:** Treatment A
- **DRUG:** Treatment B

## Key facts

- **NCT ID:** NCT01822028
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-06
- **Final completion:** 2013-08
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2015-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01822028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01822028, "Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01822028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*